A reconciliation of net income to earnings before non-cash charges is presented below (in thousands, except per share data):Three Months Ended
March 31,20112010Net income, as reported
$16,390$18,929Adjust for non-cash charges:Interest expense
5,4134,687Income tax expense
--Depreciation and amortization
5,8094,570Impairment charges (1)
36,85630,125Earnings before non-cash charges
$80,718$68,063Earnings before non-cash charges per share:Basic
$1.29$1.13Weighted average number of common shares outstanding:Basic
62,62360,019(1) Includes a $5.3 million non-cash loss recognized in connection with the sale of Medicomp, Inc., our wholly owned telemedicine subsidiary, on March 31, 2011.Conference CallWe will host a half-hour teleconference on Thursday, April 28, 2011, at 9:00 a.m. Eastern Time. The teleconference is accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533. A rebroadcast of the teleconference will be available for one week by dialing 1-800-642-1687, with international callers dialing 1-706-645-9291 and using access code 56250172.
This teleconference is also being webcast and can be accessed via our website at http://ir.unither.com/events.cfm.
About United TherapeuticsUnited Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions.
Non-GAAP Financial InformationThis press release contains a financial measure, earnings before non-cash charges, that
|SOURCE United Therapeutics Corporation|
Copyright©2010 PR Newswire.
All rights reserved